- Home
- MCRB vs MREO Comparison
MCRB vs MREO Comparison
Compare MCRB & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCRB | MREO |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.4M | 50.3M |
| IPO Year | 2015 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MCRB | MREO |
|---|---|---|
| Price | $5.49 | $0.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $14.00 | $1.50 |
| AVG Volume (30 Days) | 53.2K | ★ 5.1M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $789,000.00 | $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.32 | $0.20 |
| 52 Week High | $29.98 | $2.37 |
Technical Indicators
Market Signals| Indicator | MCRB | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 55.09 | 34.25 |
| Support Level | $5.31 | $0.22 |
| Resistance Level | $5.65 | $0.35 |
| Average True Range (ATR) | 0.33 | 0.02 |
| MACD | 0.13 | -0.00 |
| Stochastic Oscillator | 66.03 | 10.81 |
Price Performance
Historical ComparisonAbout MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).